BioToxTech Co Ltd

### Capital Structure and Liquidity BioToxTech maintains a market price of 2,910 KRW per share, with a market capitalization of 44.83 billion KRW. The company's price-to-book ratio is 0.89, indicating that the market values the company at a discount to its book value. The liquidity position is characterized as medium risk, with a current ratio of 0.81, suggesting that the company's current liabilities exceed its current assets. The company's cash and equivalents amount to 23.79 billion KRW, but this is offset by long-term debt of 58.68 billion KRW, resulting in a negative net cash position.

### Profitability and Returns BioToxTech is currently unprofitable, with a net loss of 1.29 billion KRW and an operating loss of 2.33 billion KRW. The company's return on equity (ROE) is -2.56%, and its return on assets (ROA) is -0.9%, both significantly below the industry median for pharmaceutical firms. The enterprise value to EBITDA ratio is negative at -34.21, reflecting the company's current unprofitability and the challenges it faces in generating positive cash flows from operations.

### Segments and Geographic Exposure The company operates primarily in the pharmaceuticals segment, with no disclosed geographic revenue breakdown. Given the absence of segment-specific data, it is not possible to assess the company's exposure to different markets or the performance of individual product lines.

### Growth Trajectory The company's growth trajectory is uncertain, with no disclosed revenue growth rates or future projections. Analysts estimate a mean EBIT of 18.92 billion KRW, but this is not supported by the company's current financial performance, which includes a net loss and negative operating income. The company's free cash flow is negative at -2.33 billion KRW, indicating that it is not generating sufficient cash to fund operations and capital expenditures.

### Risk Factors The company faces medium liquidity risk, with a current ratio of 0.81 and a negative net cash position. The risk of dilution is assessed as low, but the company's capital structure is heavily leveraged, with a debt-to-equity ratio of 1.16. The company's unprofitability and negative cash flows from operations pose significant risks to its financial stability.

### Recent Events Recent financial filings indicate continued losses and a reliance on long-term debt to fund operations. The company's last actual EPS was -109.00 KRW, reflecting ongoing financial challenges.

Revenue surged 44.1% year-over-year to 47 billion KRW, demonstrating strong top-line growth momentum.

Net income improved significantly with a 123.8% year-over-year increase, indicating recovering profitability trends.

Free cash flow turned positive at 527 million KRW, marking a 105.2% improvement from prior periods.

Operating income rose 40.8% year-over-year, suggesting operational efficiencies are beginning to materialize for the company.

Long-term debt decreased to 62.5 billion KRW from 63 billion KRW in FY-1, showing slight deleveraging.

Debt-to-equity ratio stands at 1.16, significantly higher than the cohort median of 0.32.

Return on equity is negative at -2.56%, underperforming the cohort median of 4.56% substantially.

The company faces high credit risk and medium liquidity risk according to current risk flag assessments.

Revenue KRW 11.42B; Operating income -KRW 1.36B.

• ▍Revenue KRW 11.42B
• ▍Operating income -KRW 1.36B
• ▍Net margin -18.5%

Revenue KRW 11.12B; Operating income -KRW 2.01B.

• ▍Revenue KRW 11.12B
• ▍Operating income -KRW 2.01B
• ▍Net margin -10.7%

Revenue KRW 9.81B; Operating income -KRW 2.82B.

• ▍Revenue KRW 9.81B
• ▍Operating income -KRW 2.82B
• ▍Net margin -18.6%

Revenue KRW 8.99B; Operating income -KRW 2.33B.

• ▍Revenue KRW 8.99B
• ▍Operating income -KRW 2.33B
• ▍Net margin -14.4%

Revenue KRW 41.34B, +26,7% YoY; Operating income −3,6% YoY.

• ▍Revenue KRW 41.34B, +26,7% YoY
• ▍Operating income −3,6% YoY
• ▍Net income −31,8% YoY
• ▍Free cash flow −7,7% YoY
• ▍Net margin -15.5%